| Previous Close | 1.2600 |
| Open | 1.2800 |
| Bid | 1.26 x 0 |
| Ask | 1.30 x 0 |
| Day's Range | 1.2500 - 1.3100 |
| 52 Week Range | 1.0700 - 3.2500 |
| Volume | 380,251 |
| Avg. Volume | 966,221 |
| Market Cap | 140.201M |
| Beta (3Y Monthly) | 3.87 |
| PE Ratio (TTM) | 28.64 |
| EPS (TTM) | 0.04 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has exported its cannabis genetics to Israel’s Pharmocann, a privately-held pharma-agricultural medical cannabis producer working under the authorization of Israel’s Ministry of Health and widely recognized as a pioneer in the worldwide medical cannabis industry. “We are delighted that Pharmocann, one of the world leaders and advocates in the medical cannabis community, has selected WeedMD’s genetics to strengthen its robust genetics library. Israel has been researching and advancing medical cannabis for well over 50 years, and Pharmocann has been providing high-quality products to medical patients for over a decade,” said Keith Merker, CEO of WeedMD.
WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has secured a licence from Health Canada to sell cannabis cultivated at its greenhouse facility in Strathroy, Ontario. The original licence, issued under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), was successfully migrated to a licence under the Cannabis Act and its regulations. The sales licence allows the Company to transport cannabis from its Strathroy greenhouse to its nearby indoor facility in Aylmer, Ontario for packaging and distribution to its medical and adult-use customers.
WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has signed a multi-year retail sales distribution agreement with Lifford Cannabis Solutions (“Lifford”), led by long-time cannabis advocate, influencer and media personality Lisa Campbell, to represent WeedMD’s premium cannabis brands and products for the adult-use retail market in British Columbia and Alberta. Lifford has a history of delivering great results in the alcohol beverage category and has developed strong relationships with the provincial distributors as well as key customers,” said Brett Moon, SVP, Sales and Marketing at WeedMD. “Lifford Cannabis Solutions is delighted to be working with WeedMD, a licensed producer widely recognized as a groundbreaking cultivator in Canada.
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, and Blockstrain Technology Corp. (DNAX.V) (BKKSF) (“Blockstrain”) are pleased to announce that they have kicked off the launch of Blockstrain’s proprietary genome tracking software following the collection and registration of WeedMD’s cannabis plant DNA. “We are now able to provide consumers with an assurance of quality and can guarantee the provenance of the strains they are buying.
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a pivotal agreement with Montreal-based Smart Medicines GMP Inc. (“Smart Medicines”) and appointed its founder and president, Dr. Domenico Fuoco, to the position of Chief Innovation Officer of WeedMD. Smart Medicines is a leading-edge, research-driven organization that creates, develops and launches pharmaceuticals, natural health products and cosmetics.
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has signed an agreement for a pilot project to convert a popular Toronto-based medical cannabis centre to a WeedMD cannabis education centre (“Education Centre”). Internationally-renowned medical cannabis advocate Amy Brown, also known as Amy Anonymous, will oversee the Education Centre with a preview “Pop-up Shop” opening on October 16-18, located at 685 Yonge Street, 2nd Floor in Toronto, Ontario.
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce its recent leadership appointments in the areas of production, sales, marketing, communications and human resources as WeedMD solidifies its market positioning, expands cannabis production, diversifies distribution channels and looks to spotlight its people and cannabis products on a national and global scale. “As we ramp up production and continue scaling for growth, we’ve positioned ourselves strategically at an extremely pivotal time and I’m thrilled to announce the appointment of a leadership team that brings a pedigree of proven experience, authenticity and a diverse skill set that will be integral to propelling WeedMD to the next level of success,” said Keith Merker, CEO of WeedMD.
WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has secured its Depository Trust Company (“DTC”) eligibility for WeedMD’s publicly traded securities. The Company will also begin trading on the OTCQX® Best Market under the ticker symbol “WDDMF” in the United States. U.S. investors can now find current financial disclosure and real-time level 2 quotes for WeedMD on www.otcmarkets.com.
Has delivered its first shipments of WeedMD-branded cannabis to contracted provinces ahead of the landmark ...
WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to provide an update on its medical cannabis program and its dedication and responsibility to putting patients first. Given the recent government announcements to impose an excise tax of $1 per gram (or 10% of the sale price) on cannabis (the “Excise Tax”), WeedMD is pleased to announce it will further support its medical-use customers by continuing to offer competitive pricing on its premium, medical-grade cannabis and that it will absorb the increased cost as a result of the Excise Tax. Scheduled to come into effect on October 17, 2018, the Excise Tax is applicable for both the recreational and the medical market on all cannabis products containing THC.
WeedMD Inc. (TSX-V:WMD) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to congratulate the team at Shoppers Drug Mart on securing a cannabis production licence from Health Canada. This licence allows Canada’s largest pharmacy chain to receive, label and test medical cannabis supplied by WeedMD and represents an important milestone for both companies. “As one of the most trusted names in pharmacy and patient support services, we congratulate Shoppers Drug Mart on clearing the first step to expanding its offerings and patient accessibility to premium medical cannabis,” said Keith Merker, CEO of WeedMD.
“WeedMD has differentiated itself by proudly supplying more than 20% of the Canadian cannabis industry with its highly-regarded cannabis strains. Today, we are honoured to be one of the first Canadian LPs to welcome an international partner with the sale and export to Australia’s Medifarm,” said Keith Merker, CEO of WeedMD.
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on WeedMD Inc. (TSX-V: WMD, OTC PINK: WDDMF) with a price target of C$3.50 / $2.70. Based in Aylmer, Ontario, Canada, WeedMD is a federally licensed producer and distributor of medical cannabis and oils under the Access to Cannabis for Medical Purposes Regulations (ACMPR).